Last Updated : October 30, 2015
Details
FilesGeneric Name:
Teduglutide
Project Status:
Complete
Therapeutic Area:
Short bowel syndrome
Manufacturer:
Shire Pharma Canada ULC/NPS Pharma Holdings Limited
Call for patient/clinician input open:
Brand Name:
Revestive
Project Line:
Reimbursement Review
Project Number:
SR0459-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Submission Type:
Initial
Indications:
Short Bowel Syndrome (SBS)
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Files
Last Updated : October 30, 2015